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A single founder allele of the CHEK2 gene has been associated with predisposition to breast and prostate cancer
in North America and Europe. The CHEK2 protein participates in the DNA damage response in many cell types
and is therefore a good candidate for a multisite cancer susceptibility gene. Three founder alleles are present in
Poland. Two of these result in a truncated CHEK2 protein, and the other is a missense substitution of an isoleucine
for a threonine. We ascertained the prevalence of each of these alleles in 4,008 cancer cases and 4,000 controls,
all from Poland. The majority of the common cancer sites were represented. Positive associations with protein-
truncating alleles were seen for cancers of the thyroid (odds ratio [OR] 4.9; ), breast (OR 2.2;Pp .0006 Pp
), and prostate (OR 2.2; ). The missense variant I157T was associated with an increased risk of breast.02 Pp .04
cancer (OR 1.4; ), colon cancer (OR 2.0; ), kidney cancer (OR 2.1; ), prostate cancerPp .02 Pp .001 Pp .0006
(OR 1.7; ), and thyroid cancer (OR 1.9; ). The range of cancers associated with mutations of thePp .002 Pp .04
CHEK2 gene may be much greater than previously thought.
The CHEK2 gene (MIM 604373) encodes the human
analogue of the yeast checkpoint kinases Cds1 andRad53
(Matsuoka et al. 1998). Activation of CHEK2 in response
to DNA damage prevents the cell from entering into mi-
tosis. The frequency of the 1100delC variant is 0.2%–
1.4% in European populations (Meijers-Heijboer et al.
2002; CHEK2 Breast Cancer Case-Control Consortium
2004), but the allele appears to be infrequent in North
America (Ofﬁt et al. 2003). This allele has been found to
confer an elevated risk of breast cancer (Meijers-Heijboer
et al. 2002; Ofﬁt et al. 2003; CHEK2 Breast Cancer Case-
Control Consortium 2004) and prostate cancer (Dong et
al. 2003; Seppala et al. 2003). It has also been reported
in excess among Dutch families with aggregates of both
breast and colon cancer (Meijers-Heijboer et al. 2003). In
Poland, there are three polymorphic variants of CHEK2,
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which, in aggregate, are present in 5.5% of the popula-
tion. Two of these (1100delC and IVS21GrA) are rare
and result in premature protein truncation; the third is a
common missense variant (I157T) that results in the sub-
stitution of an isoleucine for a threonine.We have recently
reported that all three variants are associated with an
increased risk of prostate cancer in Poland (Cybulski et
al. 2004). The CHEK2 protein is expressed in a wide
range of tissues, and the full range of cancers associated
with inactivating CHEK2 mutations has not yet been
determined.
To establish the range of cancer types associated with
CHEK2 mutations, we genotyped 4,008 cases of cancer
and 4,000 controls in Poland. We included 7 of the 10
most common types of cancer in Poland, and, together,
these sites are representative of about two-thirds of all
cancer cases in the country. Cases were collected from
hospitals in Szczecin and surrounding counties. Study
subjects were asked to participate at the time of diag-
nosis or during outpatient visits to surgical and medical
oncology clinics. In general, patient participation rates
exceeded 80% for each cancer site. Study subjects were
unselected for age, sex, and family history.
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Three control groups were combined. The ﬁrst group
consisted of 2,000 newborn children from 10 hospitals
throughout Poland (Szczecin, Bialystok, Gorzow, Katow-
ice, Wroclaw, Poznan, Opole, Lodz, and Rzeszow) in
2003 and 2004. Samples of cord blood from unselected
infants were forwarded to the study center in Szczecin.
The second control group was taken from adult patient
rolls of three family doctors practicing in the Szczecin
region. One thousand controls were selected at random
from the patient lists of these family doctors. The third
control group consisted of adults from Szczecin who sub-
mitted blood for paternity testing. A sample of DNA was
forwarded to the reference laboratory without identifying
information. To ensure the comparability of the control
groups, the allele frequencies of the three alleleswere com-
puted separately for the adult and neonatal control groups
and were compared.
We assessed the frequency of three CHEK2 variants:
IVS21GrA, 1100delC, and I157T. The IVS21GrA
mutation was identiﬁed by RFLP-PCR by use of Hpy188
III (New England Biolabs) and primers Ch2/3f (5′-ATT
TAT GAG CAA TTT TTA AAC G-3′) and Ch2/3r (5′-
TCC AGT AAC CAT AAG ATA ATA ATA TTA C-3′).
The PCR product was digested in samples in which a
mutation was present. The 430TrC variant (Ile157Thr)
was analyzed by RFLP-PCR by use of the Ch157f (5′-
A CCC ATG TAT CTA GGA GAG CTG-3′) and Ch157r
(5′-CCA CTG TGA TCT TCT ATG TCT GCA-3′) prim-
ers. The reverse primer introduced an artiﬁcial restriction
site for the PstI enzyme. The PCR products were digested
in mutation-positive samples. The 1100delC variant was
analyzed using an allele-speciﬁc PCR assay and primers
Chk2ex10f (5′-TTA ATT TAA GCA AAA TTA AAT
GTC-3′), Chk2ex10r (5′-GGC ATG GTG GTG TGC
ATC-3′), and Chk2delC (5′-TGG AGT GCC CAA AAT
CAT A-3′). All reactions were performed using Thermal
Cycler 9600 (PerkinElmer). PCR products were separated
in 2%–3% agarose gels and were visualized in UV light.
For samples in which a mutation was detected in the
RFLP-PCR and allele-speciﬁc oligonucleotides (ASO)–
PCR analyses, a separate DNA sample was sequenced to
conﬁrm the presence of the mutation.
Exons 10–14 of CHEK2 share high homology with
several pseudogenes located on chromosomes 2, 7, 10,
13, 15, 16, X, and Y (Sodha et al. 2000). To avoid
ampliﬁcation of pseudogene sequences, we designed
a forward primer (Chk2ex10f) that is speciﬁc for the
CHEK2 gene on chromosome 22 and a reverse primer
(Chk2delCr) that is speciﬁc for the 1100delC allele. In
cases that were positive for 1100delC by ASO-PCRanal-
ysis, a separate DNA sample was sequenced with the
Chk2ex10f and Chk2ex10r primers to conﬁrm the pres-
ence of the mutation. Furthermore, to conﬁrm the chro-
mosomal location of the observed CHEK2 mutations,
we analyzed the polymorphic marker D22S275, which
maps to intron 4 of CHEK2. We genotyped 36 patients
with the I157T variant, all individuals with the
1100delC or the IVS21GrA mutation, and 50 indi-
viduals from the general population. All individuals with
the 1100delC variant or the I157T variant carried the
165-bp allele of D22S275, which we estimate has a fre-
quency of 15% in the Polish population. All individuals
with the IVS21GrAmutation carried the 171-bp allele
of D22S275, which we estimate has a frequency of 8%
in the general population. These observations support
the chromosome 22 assignment for the three variant
alleles.
Statistical analysis included a comparison of the pro-
portions of the prevalence of the allele in cases and con-
trols. Odds ratios (ORs) were generated from two-by-
two tables, and statistical signiﬁcance was assessed using
the Fisher’s exact test.
The frequencies of the three CHEK2 variants in cases
and controls are presented in table 1. Because of their
different effects on protein synthesis, the two truncating
mutations (IVS21GrA or 1100delC) were considered
separately from the missense mutation (I157T). A trun-
cating CHEK2 mutation was detected in 0.7% of Polish
controls. For 6 of the 13 sites (breast, colon, melanoma,
prostate, thyroid, and stomach), the prevalence of the
mutant alleles was 11%. For three sites (breast, prostate,
and thyroid), the excess was statistically signiﬁcant. The
prevalence of the truncating CHEK2 alleles was partic-
ularly high (3.5%) in patients with thyroid cancer. The
missense CHEK2 I157T allele was found in 4.8% of
controls. This variant was more common in cancer cases
than in controls for nine sites, and for three sites (colon,
kidney, and prostate) the association was signiﬁcant at
the level.P  .01
Although any individual ﬁnding might be due to
chance, our study, on the whole, suggests that mutations
in CHEK2 increase the risk of cancer in many different
organs. A total of 52 comparisons were made. Of these,
13 were signiﬁcant at the level (2.6 expectedPp .05
by chance), and 5 were signiﬁcant at the levelPp .01
(0.5 expected). Furthermore, at all three sites for which
a signiﬁcant association was seen with the truncatingmu-
tation, a signiﬁcant association was also seen with the
missense mutation. This would be unlikely if the obser-
vations were due to chance.
Multiorgan cancer predisposition is characteristic of
other genes in the DNA damage–signaling pathway, in-
cluding BRCA1 (MIM 113705),BRCA2 (MIM600185),
and NBS1 (MIM 602667). We expected that the effects
of truncating mutations and of missense mutations might
differ. Prostate, breast, and thyroid cancerwere associated
with mutations of both types. Interestingly, kidney cancer
and colon cancer were associated with the CHEK2 mis-
sense variant but notwith truncatingmutations.However,
the number of truncating mutations in this study was
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Table 2
Frequencies of CHEK2 Variant Alleles in Adult and Newborn
Controls
CONTROL GROUP
NO. OF SUBJECTS WITH VARIANT
(FREQUENCY IN %)
IVS21GrA 1100delC I157T
Newborns ( )np 2,000 9 (.45) 5 (.25) 92 (4.6)
Adults ( )np 2,000 10 (.50) 5 (.25) 101 (5.0)
relatively small, and some associations may have been
missed as a result of limited study power.
There were no clear associations between age at onset
and the presence of a CHEK2 mutation for any of the
13 cancer sites studied. However, for all sites except colon
and thyroid, the average age at onset was younger for
carriers of truncating mutations than for noncarriers, but
the difference was not statistically signiﬁcant for any of
the comparisons. The ages at onset of cancer for patients
with and without the missense mutation were very similar
(data not shown).
Several previous observations suggest that the I157T
missense mutation is pathogenic. It is localized in a func-
tionally important domain of CHEK2 (the FHA domain),
and the protein with this mutation has been shown to be
defective in its ability to bind and phosphorylate Cdc25A
and to bind p53 and BRCA1 (Falck et al. 2001a, 2001b;
Li et al. 2002). The I157T protein may also have a dom-
inant negative effect by forming heterodimers with wild-
type CHEK2 (Kilpivaara et al. 2004). A recent paper from
Finland (Kilpivaara et al. 2004) also reported that the
CHEK2 I157T mutation was associated with an increase
in the risk of breast cancer of a magnitude similar to that
reported here (OR 1.4; ). Other groups have onlyPp .02
found an association between breast cancer risk and the
1100delC variant (Schutte et al. 2003; Dufault et al.
2004). The CHEK2 Breast Cancer Case-Control Con-
sortium (2004) reported an OR of 2.3 in association with
the 1100delC variant but did not report on other variants.
It was also reported by Kilpivaara et al. (2003) that
the 1100delC variant is not associated with colon cancer
(Kilpivaara et al. 2003). This is consistent with our ob-
servation of no increased colon cancer risk with either
truncating mutation, but we did see a highly signiﬁcant
association with the missense variant (OR 2.0; Pp
). An association of similar magnitude was seenwith.001
kidney cancer (OR 2.0; ) (to our knowledge,Pp .0006
no previous group has studied the relationship between
CHEK2 mutations and kidney cancer). All of the kidney
cancer cases were clear cell renal carcinomas. Our
strongest observed association was with thyroid cancer
(OR 4.9; ), but this estimate was based onPp .0006
only six truncating mutations and needs to be conﬁrmed.
These six cancers were all of papillary histology.
In summary, these observations support the hypoth-
esis that CHEK2 is a multisite cancer gene that increases
the risk for several cancers other than breast and prostate
cancer. This is perhaps not surprising, since CHEK2 was
ﬁrst reported to be a gene for Li-Fraumeni type families
(MIM 151623) (Bell et al. 1999), and these families suf-
fer from a wide range of cancer types. In the original
studies of the CHEK2 1100delC mutation and Li-Frau-
meni syndrome, cancers of the breast, colon, stomach,
ovary, endometrium, kidney, and prostate were reported
(Bell et al. 1999; Vahteristo et al. 2001).
Most of the patients in our case group were recruited
from the Szczecin region, which is populated by ethnic
Poles who immigrated to the region from throughout
Poland after the Second World War, as ethnic German
residents were relocated elsewhere. Our control group
was drawn both from the adult population of Szczecin
and from newborns in 10 cities throughout Poland. The
frequency of the CHEK2 alleles was similar in the new-
born and adult controls (table 2). Also, there was no
statistical difference between the CHEK2 allele frequen-
cies of the newborns recruited from the Szczecin met-
ropolitan region and those of newborns from other Po-
lish cities (data not shown).
After BRCA1 and BRCA2 were discovered in 1994
and 1995, it was hoped that the identiﬁcation of a third
rare high-risk breast cancer gene would follow—or at
least that common variants of these genes, conferring
modest lifetime cancer risks, would be detected. To date,
these genes remain undiscovered. Arguably, the most im-
portant discovery of a breast cancer gene in the past 8
years has been CHEK2, which is typical of a third cat-
egory of genes; mutations in genes in this category are
rare and are associated with modest penetrance. It is
difﬁcult to study these genes, because very large sample
sizes are needed to identify signiﬁcant relative risks. Not
all populations harbor carriers at the same frequency,
and different mutations may be associated with different
cancer risks. Large, well-controlled studies are needed
to establish the full range of risks associated with
CHEK2 founder alleles in different populations and to
estimate the corresponding risks associated with various
mutations for various cancer sites.
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